Clemens, M. J. Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene23, 3180–3188 (2004). ArticleCASPubMed Google Scholar
Averous, J. & Proud, C. G. When translation meets transformation: the mTOR story. Oncogene25, 6423–6435 (2006). ArticleCASPubMed Google Scholar
Voeller, D., Rahman, L. & Zajac-Kaye, M. Elevated levels of thymidylate synthase linked to neoplastic transformation of mammalian cells. Cell Cycle3, 1005–1007 (2004). ArticleCASPubMed Google Scholar
Rahman, L. et al. Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell5, 341–351 (2004). ArticleCASPubMed Google Scholar
Kuhajda, F. P. Fatty-acid Synthase and human cancer: new perspectives on its role in tumor biology. Nutrition16, 202–208 (2000). First review documenting the relationship between FASN-catalysed endogenous FA biogenesis and tumour biology. ArticleCASPubMed Google Scholar
Wakil, S. J. Structure and function of animal fatty acid synthase. Lipids39, 1045–1053 (2004). ArticlePubMed Google Scholar
Asturias, F. J. et al. Structure and molecular organization of mammalian fatty acid synthase. Nature Struct. Mol. Biol.12, 225–232 (2005). ArticleCAS Google Scholar
Maier, T., Jenni, S. & Ban, N. Architecture of mammalian fatty acid synthase at 4.5 Å resolution. Science311, 1258–1262 (2006). Revealed the architecture of mammalian FASN at 4.5 Å resolution for the first time. ArticleCASPubMed Google Scholar
Weiss, L. et al. Fatty-acid biosynthesis in man, a pathway of minor importance. Purification, optimal assay conditions, and organ distribution of fatty-acid synthase. Biol. Chem. Hoppe Seyler367, 905–912 (1986). ArticleCASPubMed Google Scholar
Wagle, S. et al. Hormonal regulation and cellular localization of fatty acid synthase in human fetal lung. Am. J. Physiol.277, 381–390 (1999). Google Scholar
Kusakabe, T. et al. Fatty acid synthase is expressed mainly in adult hormone-sensitive cells or cells with high lipid metabolism and in proliferating fetal cells. J. Histochem. Cytochem.48, 613–622 (2000). ArticleCASPubMed Google Scholar
Pizer, E. S. et al. Expression of fatty acid synthase is closely linked to proliferation and stromal decidualization in cycling endometrium. Int. J. Gynecol. Pathol.16, 45–51 (1997). ArticleCASPubMed Google Scholar
Anderson, S. M. et al. Key stages in mammary gland development. Secretory activation in the mammary gland: it's not just about milk protein synthesis! Breast Cancer Res.9, 204 (2007). An up-to-date review exhaustively describing all the hormonal regulation pathways that are involved in the mammary gland transition from pregnancy to lactating breast, a highly efficient lipid synthetic organ. ArticlePubMedPubMed CentralCAS Google Scholar
Medes, G., Thomas, A. & Weinhouse, S. Metabolism of neoplastic tissue IV: a study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res.13, 27–29 (1953). One of the pioneer studies describing the existence of exacerbated endogenous FA metabolism in tumour tissues. CASPubMed Google Scholar
Szutowicz, A., Kwiatkowski, J. & Angielski, S. Lipogenetic and glycolytic enzyme activities in carcinoma and nonmalignant diseases of the human breast. Br. J. Cancer39, 681–687 (1979). ArticleCASPubMedPubMed Central Google Scholar
Kuhajda, F. P., Piantadosi, S. & Pasternack, G. P. Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N. Engl. J. Med.321, 636–641 (1989). ArticleCASPubMed Google Scholar
Kuhajda, F. P. et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc. Natl Acad. Sci. USA91, 6379–6383 (1994). Key finding characterizing the breast tumour-associated protein OA-519 as the enzyme FASN. ArticleCASPubMedPubMed Central Google Scholar
Menendez, J. A. & Lupu, R. Fatty acid synthase-catalyzed de novo fatty acid biosynthesis: from anabolic-energy-storage pathway in normal tissues to jack-of-all-trades in cancer cells. Arch. Immunol. Ther. Exp. (Warsz.)52, 414–426 (2004). CAS Google Scholar
Swinnen, J. V., Brusselmans, K. & Verhoeven, G. Increased lipogenesis in cancer cells: new players, novel targets. Curr. Opin. Clin. Nutr. Metab. Care9, 358–365 (2006). ArticleCASPubMed Google Scholar
Menendez, J. A. & Lupu, R. Oncogenic properties of the endogenous fatty acid metabolism: molecular pathology of fatty acid synthase in cancer cells. Curr. Opin. Clin. Nutr. Metab. Care9, 346–357 (2006). ArticleCASPubMed Google Scholar
Kuhajda, F. P. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res.66, 5977–5980 (2006). ArticleCASPubMed Google Scholar
Jackowski, S. Coordination of membrane phospholipid synthesis with cell cycle. J. Biol. Chem.269, 3858–3867 (1994). CASPubMed Google Scholar
Costello, L. C. & Franklin, R. B. Tumor cell metabolism: the marriage of molecular genetics and proteomics with cellular intermediary metabolism; proceed with caution. Molecular Cancer5, 59 (2006). ArticlePubMedPubMed CentralCAS Google Scholar
Costello, L. C. & Franklin, R. B. “Why do tumour cells glycolyse”?: from glycolysis through citrate to lipogenesis. Mol. Cell. Biochem.280, 1–8 (2005). ArticleCASPubMedPubMed Central Google Scholar
Pizer, E. S. et al. Fatty acid synthase (FAS): A target for cytotoxic metabolites in HL60 promyelocitic leukemia cells. Cancer Res.56, 745–751 (1996). CASPubMed Google Scholar
Swinnen, J. V. et al. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem. Biophys. Res. Commun.302, 898–903 (2003). ArticleCASPubMed Google Scholar
Bauer, D. E. et al. ATP citrate lyase is an important component of cell growth and transformation. Oncogene24, 6314–6322 (2005). ArticleCASPubMed Google Scholar
Hatzivassiliou, G. et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell8, 311–321 (2005). ArticleCASPubMed Google Scholar
Tong, L. Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and attractive target for drug discovery. Cell. Mol. Life Sci.62, 1784–1803 (2005). ArticleCASPubMed Google Scholar
Milgraum, L. Z. et al. Enzymes of the fatty acid synthase pathway are highly expressed in in situ breast carcinoma. Clin. Cancer Res.3, 2115–2120 (1997). CASPubMed Google Scholar
Brusselmans, K. et al. RNA interference-mediated silencing of the acetyl-CoA carboxylase-α gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res.65, 6719–6725 (2005). ArticleCASPubMed Google Scholar
Chajès, V. et al. Acetyl-CoA carboxylase α is essential to breast cancer cell survival. Cancer Res.66, 5287–5294 (2006). ArticlePubMedCAS Google Scholar
Sinilnikova, O. M. et al. Acetyl-CoA carboxylase α gene and breast cancer susceptibility. Carcinogenesis25, 2417–2424 (2004). ArticleCASPubMed Google Scholar
Sinilnikova, O. M. et al. Haplotype-based analysis of common variation in the acetyl-CoA carboxylase a gene and breast cancer risk: A case-control study nested within the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol. Biomarkers Prev.16, 409–415 (2007). ArticleCASPubMed Google Scholar
Chin, K. et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell10, 529–541 (2006). ArticleCASPubMed Google Scholar
Jensen, V. et al. The prognostic value of oncogenic antigen-519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer. J. Pathol.176, 343–352 (1995). ArticleCASPubMed Google Scholar
Alo, P. L. et al. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer77, 474–482 (1996). ArticleCASPubMed Google Scholar
Gansler, T. S. et al. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum. Pathol.28, 686–692 (1997). ArticleCASPubMed Google Scholar
Alo, P. L. et al. Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas. Tumori.85, 35–40 (1999). ArticleCASPubMed Google Scholar
Visca, P. et al. Fatty acid synthase (FAS) is a marker of increased risk of recurrence in lung carcinoma. Anticancer Res.24, 4169–4173 (2004). CASPubMed Google Scholar
Sebastian, V. et al. Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma. Gynecol. Oncol.92, 101–105 (2004). ArticleCAS Google Scholar
Bandyopadhyay, S. et al. FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis. Oncogene24, 5389–5395 (2005). ArticleCASPubMed Google Scholar
Sinclair, C. S. et al. The 17q23 amplicon and breast cancer. Breast Cancer Res. Treat.78, 313–322 (2003). ArticleCASPubMed Google Scholar
Shah, U. S. et al. Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma. Hum. Pathol.37, 401–409 (2006). ArticleCASPubMed Google Scholar
Katsurada, A. et al. Effects of nutrients and hormones on transcriptional and post-transcriptional regulation of fatty acid synthase in liver. Eur. J. Biochem.190, 427–433 (1990). ArticleCASPubMed Google Scholar
Sul, H. S. & Wang, D. Nutritional and hormonal regulation of enzymes in fat synthesis: studies of fatty acid synthase and mitochondrial glycerol-3-phosphate acyltransferase gene transcription. Annu. Rev. Nutr.18, 331–351 (1998). ArticleCASPubMed Google Scholar
Fukuda, H. et al. Transcriptional regulation of fatty acid synthase by insulin/glucose, polyunsaturated fatty acids and leptin in hepatocytes and adipocytes in normal and genetically obese rats. Eur. J. Biochem.260, 505–511 (1999). ArticleCASPubMed Google Scholar
Swinnen, J. V. et al. Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway. Oncogene19, 5173–5181 (2000). First study to reveal how exacerbated GF–GFR signalling in cancer cells constitutively upregulates tumour-associated FASN. ArticleCASPubMed Google Scholar
Oskouian, B. Overexpression of fatty acid synthase in SKBR3 breast cancer cell line is mediated via a transcriptional mechanism. Cancer Lett.149, 43–51 (2000). ArticleCASPubMed Google Scholar
Kumar-Sinha, C. et al. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res.63, 132–139 (2003). CASPubMed Google Scholar
Menendez, J. A. et al. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis. Int. J. Oncol.24, 1369–1383 (2004). CASPubMed Google Scholar
Menendez, J. A. et al. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (_erb_B-2) oncogene-induced malignant transformation. Mol. Carcinog.41, 164–178 (2004). ArticleCASPubMed Google Scholar
Zhang, D. et al. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol. Cell Proteomics4, 1686–1696 (2005). ArticleCASPubMed Google Scholar
Van de Sande, T. et al. Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res.62, 642–646 (2002). CASPubMed Google Scholar
Porstmannm, T. et al. PKB/AKT induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene24, 6465–6481 (2005). ArticleCAS Google Scholar
Yang, Y. A. et al. Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp. Cell Res.279, 80–90 (2002). ArticleCASPubMed Google Scholar
Wang, H. Q. et al. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene24, 3574–3582 (2005). ArticleCASPubMed Google Scholar
Chalbos, D. et al. Fatty acid synthetase and its mRNA are induced by progestins in breast cancer cells. J. Biol. Chem.262, 9923–9926 (1987). CASPubMed Google Scholar
Swinnen, J. V. et al. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Cancer Res.57, 1086–1090 (1997). CASPubMed Google Scholar
Menendez, J. A. et al. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. Int. J. Oncol.26, 1507–1515 (2005). CASPubMed Google Scholar
Lupu, R. & Menendez, J. A. Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators? Endocrinology147, 4056–4066 (2006). This review provides new insights on the cross-talk between tumour-associated FASN and oestrogen receptor (ER) in hormone-sensitive human tumours. ArticleCASPubMed Google Scholar
Rawson, R. B. The SREBP pathway—insights from Insigs and insects. Nature Rev. Mol. Cell Biol.4, 631–640 (2003). ArticleCAS Google Scholar
Eberle, D. et al. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie.86, 839–848 (2004). References 67 and 68 brilliantly review the role of SREBP transcription factors as master regulators of lipid homeostasis. ArticleCASPubMed Google Scholar
Kim, J. B. et al. Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J. Clin. Invest.101, 1–9 (1998). ArticleCASPubMedPubMed Central Google Scholar
Shimano, H. et al. Sterol regulatory element-binding protein 1 as a key transcription factor for nutritional induction of lipogenic enzymes genes. J. Biol. Chem.274, 35832–35839 (1999). ArticleCASPubMed Google Scholar
Fleischmann, M. & Iynedjian, P. B. Regulation of sterol regulatory-element binding protein 1 gene expression in liver: role of insulin and protein kinase B/cAkt. Biochem. J.349, 13–17 (2000). ArticleCASPubMedPubMed Central Google Scholar
Kotzka, J. et al. Sterol regulatory element binding proteins (SREBP)-1a and SREBP-2 are linked to the MAP-kinase cascade. J. Lipid Res.41, 99–108 (2000). CASPubMed Google Scholar
Swinnen, J. V. et al. Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins. Proc. Natl Acad. Sci. USA94, 12975–12980 (1997). ArticleCASPubMedPubMed Central Google Scholar
Yang, Y. A. et al. Regulation of fatty acid synthase expression in breast cancer by sterol regulatory elements binding protein-1c. Exp. Cell Res.282, 132–137 (2003). ArticleCASPubMed Google Scholar
Ettinger, S. L. et al. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res.64, 2212–2221 (2004). ArticleCASPubMed Google Scholar
Menendez, J. A., Decker, J. P. & Lupu, R. In support of fatty acid synthase (FAS) as a metabolic oncogene: extracellular acidosis acts in an epigenetic fashion activating FAS gene expression in cancer cells. J. Cell. Biochem.94, 1–4 (2005). ArticleCASPubMed Google Scholar
Heemers, H. et al. Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway. Mol. Endocrinol.15, 1817–1828 (2001). ArticleCASPubMed Google Scholar
Menendez, J. A., Colomer, R. & Lupu, R. Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids? Med. Hypotheses64, 342–349 (2005). ArticleCASPubMed Google Scholar
Li, J. N. et al. Sterol regulatory element-binding protein-1 participates in the regulation of fatty acid synthase expression in colorectal neoplasia. Exp. Cell. Res.261, 159–165 (2000). ArticleCASPubMed Google Scholar
Swinnen, J. V. Increased lipogenesis in steroid-responsive cancer cells: mechanisms of regulation, role in cancer cell biology and perspectives on clinical applications. Verh. K. Acad. Geneeskd. Belg.63, 321–333 (2001). CASPubMed Google Scholar
Graner, E. et al. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell5, 253–261 (2004). The first study to describe how tumour-associated FASN overexpression can be achieved through protein stabilization. ArticleCASPubMed Google Scholar
Priolo, C. et al. The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res.66, 8625–8632 (2006). ArticleCASPubMed Google Scholar
Swinnen, J. V. et al. Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int. J. Cancer88, 176–179 (2000). ArticleCASPubMed Google Scholar
Swinnen, J. V. et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int. J. Cancer98, 19–22 (2002). ArticleCASPubMed Google Scholar
Esslimani-Sahla, M. et al. Increased expression of fatty acid synthase and progesterone receptor in early steps of human mammary carcinogenesis. Int. J. Cancer120, 224–229 (2007). ArticleCASPubMed Google Scholar
Pizer, E. S. et al. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res.56, 1189–1193 (1996). CASPubMed Google Scholar
Pizer, E. S. et al. Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res.12, 2745–2747 (1996). Google Scholar
Pizer, E. S. et al. Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res.58, 4611–4615 (1998). CASPubMed Google Scholar
Pizer, E. S. et al. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res.60, 213–218 (2000). CASPubMed Google Scholar
Li, J. N. et al. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res.61, 1493–1499 (2001). CASPubMed Google Scholar
Kuhajda, F. P. et al. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc. Natl Acad. Sci. USA97, 3450–3454 (2000). ArticleCASPubMedPubMed Central Google Scholar
Thupari, J. N., Pinn, M. L. & Kuhajda, F. P. Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem. Biophys. Res. Commun.285, 217–223 (2001). ArticleCASPubMed Google Scholar
Heiligtag, S. J., Bredehorst, R. & Davidm K. A. Key role of mitochondria in cerulenin-mediated apoptosis. Cell Death Differ.9, 1017–1025 (2002). ArticleCASPubMed Google Scholar
Liu, B. et al. Triclosan inhibits enoyl-reductase of type I fatty acid synthase in vitro and is cytotoxic to MCF-7 and SKBr-3 breast cancer cells. Cancer Chemother. Pharmacol.49, 187–193 (2002). ArticleCASPubMed Google Scholar
Zhou, W. et al. Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res.63, 7330–7337 (2003). CASPubMed Google Scholar
Brusselmans, K. et al. Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. Int. J. Cancer106, 856–862 (2003). ArticleCASPubMed Google Scholar
Menendez, J. A. et al. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells. Oncogene23, 4945–4958 (2004). ArticleCASPubMed Google Scholar
Menendez, J. A. et al. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-κB. Int. J. Oncol.24, 591–608 (2004). CASPubMed Google Scholar
Kridel, S. J. et al. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res.64, 2070–2075 (2004). ArticleCASPubMed Google Scholar
Knowles, L. M. et al. A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2. J. Biol. Chem.279, 30540–30545 (2004). ArticleCASPubMed Google Scholar
Menendez, J. A., Vellon, L. & Lupu, R. Antitumoral actions of the anti-obesity drug orlistat (Xenical™) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann. Oncol.16, 1253–1267 (2005). ArticleCASPubMed Google Scholar
Menendez, J. A. & Lupu, R. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells. Int. J. Mol. Med.15, 33–40 (2005). CASPubMed Google Scholar
Bandyopadhyay, S. et al. Mechanism of apoptosis induced by the inhibition of fatty acid synthase in breast cancer cells. Cancer Res.66, 5934–5940 (2006). ArticleCASPubMed Google Scholar
Lupu, R. & Menendez, J. A. Pharmacological inhibitors of fatty acid synthase (FASN)-catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Curr. Pharm. Biotechnol.7, 495–502 (2006). ArticlePubMed Google Scholar
Menendez, J. A. et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc. Natl Acad. Sci. USA101, 10715–10720 (2004). First experimental evidence showing the ability of endogenous FA metabolism to specifically regulate well-characterized oncogenes such as ERBB2. ArticleCASPubMedPubMed Central Google Scholar
Menendez, J. A., Lupu, R. & Colomer, R. Targeting fatty acid synthase: potential for therapeutic intervention in Her-2/neu-overexpressing breast cancer. Drug News Perspect.18, 375–385 (2005). ArticleCASPubMed Google Scholar
Gatenby, R. A. & Gawlinski, E. T. The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res.63, 3847–3854 (2003). CASPubMed Google Scholar
Gatenby, R. A. & Gillies, R. J. Why do cancers have high aerobic glycolysis? Nature Rev. Cancer4, 891–899 (2004). A compelling opinion piece, in which the authors convincingly propose that the glycolytic phenotype confers a significant proliferative advantage during somatic evolution of cancer and must, therefore, be a crucial component of the malignant phenotype. ArticleCAS Google Scholar
Gillies, R. J. & Gatenby, R. A. Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Rev.26, 311–317 (2007). ArticleCASPubMed Google Scholar
Gatenby, R. A. & Gillies, R. J. Glycolysis in cancer: a potential target for therapy. Int. J. Biochem. Cell Biol.39, 1358–1366 (2007). ArticleCASPubMed Google Scholar
Hochachka, P. W. Living without oxygen. 1–181 (Harvard University Press, Cambridge, USA, 1980). Book Google Scholar
Hochachka, P. W. et al. Going malignant: the hypoxia-cancer connection in the prostate. Bioessays24, 749–757 (2002). ArticleCASPubMed Google Scholar
Baron, A. et al. Fatty acid synthase: a metabolic oncogene in prostate cancer? J. Cell. Biochem.91, 47–53 (2004). ArticleCASPubMed Google Scholar
Elstrom, R. L. et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res.64, 3892–3899 (2004). ArticleCASPubMed Google Scholar
Buzzai, M. et al. The glucose dependence of Akt-transformed cells can be reversed by pharmacological activation of fatty acid-beta oxidation. Oncogene24, 4165–4173 (2005). ArticleCASPubMed Google Scholar
Gatenby, R. A. et al. Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res.66, 5216–5223 (2006). ArticleCASPubMed Google Scholar
Smallbone, K. et al. Metabolic changes during carcinogenesis: potential impact on invasiveness. J. Theor. Biol.244, 703–713 (2007). ArticleCASPubMed Google Scholar
Visca, P. et al. Immunohistochemical expression and prognostic significance of FAS and GLUT1 in bladder carcinoma. Anticancer Res.23, 335–339 (2003). CASPubMed Google Scholar
Alo, P. L. et al. Immunohistochemical expression of human erythrocyte glucose transporter and fatty acid synthase in infiltrating breast carcinomas and adjacent typical/atypical hyperplastic or normal breast tissue. Am. J. Clin. Pathol.116, 129–134 (2001). ArticleCASPubMed Google Scholar
Semenza, G. L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med.8, 62–67 (2002). Article Google Scholar
Semenza, G. L. Targeting HIF-1 for cancer therapy. Nature Rev. Cancer3, 721–732 (2003). ArticleCAS Google Scholar
Laughner, E. et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell Biol.21, 3995–4004 (2001). ArticleCASPubMedPubMed Central Google Scholar
Li, J. et al. Altered metabolic response to intermittent hypoxia in mice with partial deficiency of hypoxia-inducible factor-1α. Physiol. Genomics25, 450–457 (2006). ArticleCASPubMed Google Scholar
Menendez, J. A . et al. Does endogenous fatty acid metabolism allow cancer cells to sense hypoxia and mediate hypoxic vasodilatation? Characterization of a novel molecular connection between fatty acid synthase (FAS) and hypoxia-inducible factor-1α (HIF-1α)-related expression of vascular endothelial growth factor (VEGF) in cancer cells overexpressing Her-2/neu oncogene. J. Cell. Biochem.94, 857–863 (2005). ArticleCASPubMed Google Scholar
Pflug, B. R. et al. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model. Prostate57, 245–254 (2003). ArticleCASPubMed Google Scholar
Rossi, S. et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol. Cancer Res.1, 707–715 (2003). CASPubMed Google Scholar
De Schrijver, E. et al. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res.63, 3799–3804 (2003). CASPubMed Google Scholar
Menendez, J. A. et al. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. Int. J. Cancer.115, 19–35 (2005). First experimental evidence demonstrating a role for FASN in the response of cancer cells to chemotherapy. ArticleCASPubMed Google Scholar
Menendez, J. A., Colomer, R. & Lupu, R. Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells. Oncol Rep.12, 411–422 (2004). CASPubMed Google Scholar
Menendez, J. A., Lupu, R. & Colomer, R. Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER-2/neu-overexpressing human breast cancer cells to docetaxel (taxotere). Breast Cancer Res. Treat.84, 183–195 (2004). ArticleCASPubMed Google Scholar
Lu, S. & Archer, M. C. Fatty acid synthase is a potential molecular target for the chemoprevention of breast cancer. Carcinogenesis26, 153–157 (2005). ArticleCASPubMed Google Scholar
Alli, P. M. et al. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene24, 39–46 (2005). Thisin vivostudy supports the notion of targeting FASN as a valuable approach in breast cancer chemoprevention. ArticleCASPubMed Google Scholar
Cunningham, B. A. et al. “Spot 14” protein: a metabolic integrator in normal and neoplastic cells. Thyroid8, 815–825 (1998). ArticleCASPubMed Google Scholar
Moncur, J. T. et al. The “Spot 14” gene resides on the telomeric end of the 11q13 amplicon and is expressed in lipogenic breast cancers: implications for control of tumor metabolism. Proc. Natl Acad. Sci. USA95, 6989–6994 (1998). ArticleCASPubMedPubMed Central Google Scholar
Wells, W. A. et al. Expression of “Spot 14” (THRSP) predicts disease free survival in invasive breast cancer: immunohistochemical analysis of a new molecular marker. Breast Cancer Res. Treat.98, 231–240 (2006). ArticleCASPubMed Google Scholar
Martel, P. M. et al. S14 protein in breast cancer cells: direct evidence of regulation by SREBP-1c, superinduction with progestin, and effects on cell growth. Exp. Cell Res.312, 278–288 (2006). CASPubMed Google Scholar
Kinlaw, W. B. et al. Spot 14: A marker of aggressive breast cancer and a potential therapeutic target. Endocrinology147, 4048–4055 (2006). ArticleCASPubMed Google Scholar
Magnard, C. et al. BRCA1 interacts with acetyl-CoA carboxylase throuch its tandem of BRCT domains. Oncogene21, 6729–6739 (2002). ArticleCASPubMed Google Scholar
Moreau, K. et al. BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase. J. Biol. Chem.281, 3172–3181 (2006). This study reveals that neoplastic lipogenesis may associate with an increased susceptibility to breast and ovarian cancer through BRCA1. ArticleCASPubMed Google Scholar
Brunet, J. et al. BRCA1 and Acetyl-CoA Carboxylase: The metabolic syndrome of breast cancer. Mol. Carcinog. 9 July 2007 [Epub ahead of print].
Hardie, D. G. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology144, 5179–5183 (2003). ArticleCASPubMed Google Scholar
Luo, Z. et al. AMPK, the metabolic syndrome and cancer. Trends Pharmacol. Sci.26, 69–76 (2005). ArticleCASPubMed Google Scholar
Swinnen, J. V. et al. Mimicry of a cellular low energy status blocks tumor cells anabolism and suppresses the malignant phenotype. Cancer Res.65, 2441–2448 (2005). Provides clear evidence that the energy status of tumour cells is crucial in the maintenance of the transformed phenotype. ArticleCASPubMed Google Scholar
Guastamacchia, E. et al. Evidence for a putative relationship between type 2 diabetes and neoplasia with particular reference to breast cancer: Role of hormones, growth factors and specific receptors. Curr. Drug Targets Immune. Endocr. Metabol. Disord.4, 59–66 (2004). ArticleCASPubMed Google Scholar
Resta, F. et al. The impact of body mass index and type 2 diabetes on breast cancer: current therapeutic measures of prevention. Curr. Drug Targets Immune Endocr. Metabol. Disord.4, 327–333 (2004). ArticleCASPubMed Google Scholar
Zakikhani, M. et al. Metformin is an AMPK kinase-dependent growth inhibitor for breast cancer cells. Cancer Res.66, 10269–10273 (2007). Article Google Scholar
Pemble, C. W. IIII et al. Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat. Struct. Mol. Biol.14, 704–709 (2007). This report should provide an excellent base from which to develop new anti-FASN agents with therapeutic value. ArticleCAS Google Scholar
Knowles, L. M. & Smith, J. W. Genome-wide changes accompanying knockdown of fatty acid synthase in breast cancer. BMC Genomics8, 168 (2007). ArticlePubMedPubMed CentralCAS Google Scholar
Little, J. L. et al. Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. Cancer Res.67, 1262–1269, 2007. ArticleCASPubMed Google Scholar
Buzzai, M. et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res.67, 6745–6752 (2007). ArticleCASPubMed Google Scholar
Yorimitsu, T. & Klionsky, D. J. Endoplasmic reticulum stress: a new pathway to induce autophagy. Autophagy3, 160–162 (2007). ArticleCASPubMed Google Scholar
Degenhardt, K. et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell.10, 51–64 (2006). ArticleCASPubMedPubMed Central Google Scholar
Jin, S. & White, E. Role of autophagy in cancer: management of metabolic stress. Autophagy3, 28–31 (2007). ArticleCASPubMed Google Scholar
Jin, S. et al. Metabolic catastrophe as a means to cancer cell death. J.Cell. Sci.120, 379–378 (2007). ArticleCASPubMed Google Scholar
Rodriguez-Gonzalez, A. et al. Inhibition of choline kinase renders a highly selective cytotoxic effect in tumour cells through a mitochondrial independent mechanism. Int. J. Oncol.26, 999–1008 (2005). CASPubMed Google Scholar
Helms, J. B. & Zurzolo, C. Lipids as targeting signals: lipid rafts and intracellular trafficking. Traffic5, 247–254 (2004). ArticleCASPubMed Google Scholar
Nagy, P. et al. Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. J. Cell Sci.115, 4251–4262 (2002). ArticleCASPubMed Google Scholar
Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nature Rev. Mol. Cell Biol.2, 127–137 (2001). ArticleCAS Google Scholar
Nahta, R. et al. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nature Clin. Pract. Oncol.3, 269–280 (2006). ArticleCAS Google Scholar
Xing, X. The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nature Med.6, 189–195 (2000). ArticleCASPubMed Google Scholar
Hurst, H. C. Update of HER-2 as a target for cancer therapy: the ERBB2 promoter and its exploitation for cancer treatment. Breast Cancer Res.3, 395–398 (2001). ArticleCASPubMedPubMed Central Google Scholar
Menendez, J. A. et al. A genomic explanation connecting “Mediterranean diet”, olive oil and cancer: oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory “PEA3 transcription factor-PEA3 DNA binding site” complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells. Eur. J. Cancer42, 2425–2432 (2006). ArticleCASPubMed Google Scholar
Citri, A. & Yarden, Y. EGF-ERBB signalling: towards the systems level. Nature Rev. Mol. Cell Biol.7, 505–516 (2006). ArticleCAS Google Scholar
Menendez, J. A., Vellon, L. & Lupu, R. Orlistat: from antiobesity drug to anticancer agent in Her-2/neu (erbB-2)-overexpressing gastrointestinal tumors? Exp. Biol. Med (Maywood)230, 151–154 (2005). ArticleCAS Google Scholar
Loftus, T. M. et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science288, 2379–2381 (2000). ArticleCASPubMed Google Scholar
Wortman, M. D. et al. C75 inhibits food intake by increasing CNS glucose metabolism. Nature Med.9, 483–485 (2003). ArticleCASPubMed Google Scholar
Wang, X. & Tian, W. Green tea epigallocatechin gallate: a natural inhibitor of fatty-acid synthase. Biochem. Biophys. Res. Commun.288, 1200–1206 (2001). ArticleCASPubMed Google Scholar
Brusselmans, K. et al. Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J. Biol. Chem.280, 5636–5645 (2005). ArticleCASPubMed Google Scholar